...
首页> 外文期刊>Critical care : >Experience with use of extracorporeal life support for severe refractory status asthmaticus in children
【24h】

Experience with use of extracorporeal life support for severe refractory status asthmaticus in children

机译:使用体外生命支持治疗儿童严重难治性哮喘的经验

获取原文
           

摘要

IntroductionSevere status asthmaticus (SA) in children may require intubation and mechanical ventilation with a subsequent increased risk of death. In the patient with SA and refractory hypercapnoeic respiratory failure, use of extracorporeal life support (ECLS) has been anecdotally reported for carbon dioxide removal and respiratory support. We aimed to review the experience of a single paediatric centre with the use of ECLS in children with severe refractory SA, and to compare this with international experience from the Extracorporeal Life Support Organization (ELSO) registry.MethodsAll paediatric patients (aged from 1 to 17 years) with primary International Classification of Diseases (ICD)-9 diagnoses of SA receiving ECLS for respiratory failure from both the Children's Healthcare of Atlanta at Egleston (Children's at Egleston) database and the ELSO registry were reviewed.ResultsThirteen children received ECLS for refractory SA at the Children's at Egleston from 1986 to 2007. The median age of the children was 10 years (range 1 to 16 years). Patients generally received aggressive use of medical and anaesthetic therapies for SA before cannulation with a median partial pressure of arterial carbon dioxide (PaCO2) of 130 mmHg (range 102 to 186 mmHg) and serum pH 6.89 (range 6.75 to 7.03). The median time of ECLS support was 95 hours (range 42 to 395 hours). All 13 children survived without neurological sequelae. An ELSO registry review found 64 children with SA receiving ECLS during the same time period (51 excluding the Children's at Egleston cohort). Median age, pre-ECLS PaCO2 and pH were not different in non-Children's ELSO patients. Overall survival was 60 of 64 (94%) children, including all 13 from the Children's at Egleston cohort. Survival was not significantly associated with age, pre-ECLS PaCO2, pH, cardiac arrest, mode of cannulation or time on ECLS. Significant neurological complications were noted in 3 of 64 (4%) patients; patients with neurological complications were not significantly more likely to die (P = 0.67).ConclusionsSingle centre and ELSO registry experience provide results of a cohort of children with refractory SA managed with ECLS support. Further study is necessary to determine if use of ECLS in this setting produces better outcomes than careful mechanical ventilation and medical therapy alone.
机译:简介儿童的重度哮喘(SA)可能需要插管和机械通气,继而增加死亡风险。据报道,在患有SA和难治性高碳酸血症性呼吸衰竭的患者中,使用体外生命支持(ECLS)可去除二氧化碳和呼吸支持。我们的目的是回顾单个儿童中心在重度难治性SA患儿中使用ECLS的经验,并将其与体外生命支持组织(ELSO)注册中心的国际经验进行比较。方法所有儿童患者(1至17岁)年),主要对国际疾病分类(ICD)-9诊断为SA的ECLS进行了呼吸衰竭的ECLS诊断,这些诊断来自埃格勒斯顿的亚特兰大儿童保健(Egleston的儿童)数据库和ELSO注册中心。结果有13名儿童因难治性SA接受了ECLS。 1986年至2007年在埃格斯顿儿童学校就读。儿童的平均年龄为10岁(范围为1至16岁)。患者通常在插管前积极使用SA的药物和麻醉疗法,其动脉二氧化碳分压(PaCO2)的中值分压为130 mmHg(范围为102至186 mmHg),血清pH为6.89(范围为6.75至7.03)。 ECLS支持的中位时间为95小时(范围为42到395小时)。所有13名儿童均存活下来,没有神经系统后遗症。 ELSO注册管理机构的审查发现,有64名SA患儿在同一时期接受ECLS治疗(51名不包括Egleston队列中的儿童)。非儿童ELSO患者的中位年龄,ECLS前PaCO2和pH值无差异。总体存活率为64名儿童中的60名(94%),其中包括13名来自埃格斯顿队列中的儿童。存活率与年龄,ECLS前PaCO2,pH,心脏骤停,插管方式或ECLS时间无关。 64名患者中有3名(4%)注意到严重的神经系统并发症;有神经系统并发症的患者死亡的可能性不大(P = 0.67)。结论单中心和ELSO注册经验提供了一组由ECLS支持治疗的难治性SA儿童的结果。要确定在这种情况下使用ECLS是否比单独进行仔细的机械通气和药物治疗产生更好的结果,还需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号